Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome | SpringerLink https://t.co/D2wmn8IaFD
Single low-dose #Rituximab is as efficient as conventional regimen in pediatric #FRNS https://t.co/MMQT9PtStI
RT @YincentTse: We have been using infrequent single low doses of 375mg/m2 rituximab to treat steroid sensitive nephrotic syndrome. Great t…
RT @YincentTse: We have been using infrequent single low doses of 375mg/m2 rituximab to treat steroid sensitive nephrotic syndrome. Great t…
RT @YincentTse: We have been using infrequent single low doses of 375mg/m2 rituximab to treat steroid sensitive nephrotic syndrome. Great t…
RT @Ped_Neph: 🆕🔓🆓 #openaccess Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome https://t.co/vKw6…
RT @ASPNeph: Low-dose rituximab is no less effective for #nephrotic syndrome measured by 12-month outcome https://t.co/HbuDLzPMj8 @Ped_Neph
RT @YincentTse: We have been using infrequent single low doses of 375mg/m2 rituximab to treat steroid sensitive nephrotic syndrome. Great t…
RT @YincentTse: We have been using infrequent single low doses of 375mg/m2 rituximab to treat steroid sensitive nephrotic syndrome. Great t…
RT @docdrewm: Yes - great to have this published, @EMEESYkidney data included in this collaborative work https://t.co/RmfArk9eIu
Yes - great to have this published, @EMEESYkidney data included in this collaborative work
We have been using infrequent single low doses of 375mg/m2 rituximab to treat steroid sensitive nephrotic syndrome. Great to collaborate with UK colleagues to demonstrate effectiveness https://t.co/ZGsrEjKLrd https://t.co/oIm21KCL9l
RT @Ped_Neph: 🆕🔓🆓 #openaccess Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome https://t.co/vKw6…
🆕🔓🆓 #openaccess Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome https://t.co/vKw6fnfZkN @nottmchildrens @NHSGGC @GCH_Charity @NewcastleHosps @GreatNorthCH https://t.co/71g6mwhrPA
RT @ASPNeph: Low-dose rituximab is no less effective for #nephrotic syndrome measured by 12-month outcome https://t.co/HbuDLzPMj8 @Ped_Neph
RT @ASPNeph: Low-dose rituximab is no less effective for #nephrotic syndrome measured by 12-month outcome https://t.co/HbuDLzPMj8 @Ped_Neph
RT @ASPNeph: Low-dose rituximab is no less effective for #nephrotic syndrome measured by 12-month outcome https://t.co/HbuDLzPMj8 @Ped_Neph
RT @ASPNeph: Low-dose rituximab is no less effective for #nephrotic syndrome measured by 12-month outcome https://t.co/HbuDLzPMj8 @Ped_Neph
Significant issue for nephrologists Why dont we try low dose with a nerve??!!! https://t.co/8QDz7tFYDd
RT @ASPNeph: Low-dose rituximab is no less effective for #nephrotic syndrome measured by 12-month outcome https://t.co/HbuDLzPMj8 @Ped_Neph
Low-dose rituximab is no less effective for #nephrotic syndrome measured by 12-month outcome https://t.co/HbuDLzPMj8 @Ped_Neph